Bioinfo Top 5

Feb 16 - 22, 2026

Single-Cell Atlases, CNV Detection, and Metagenomics Advances

February 28, 2026

What if you could harmonize single-cell data across all human tissues? Can we detect cancer CNVs more accurately with personalized baselines? How does overlapping raw nanopore signals improve assembly? This week's top bioinformatics breakthroughs answer these questions and more.

Cross-Tissue Single-Cell Atlas Update

A new public atlas release improves harmonization across tissues and batches, making downstream comparative cell-state analysis more reliable. This resource enables researchers to integrate single-cell data from multiple studies and laboratories, reducing technical variation while preserving biological signals. The harmonized atlas supports discovery of cell types and states across the human body.

PScnv: Personalized CNV Detection

A new framework called PScnv provides personalized self-normalizing copy number variation detection with a hierarchical multi-phase approach. This method improves detection accuracy by learning patient-specific background signals, enabling more sensitive identification of somatic CNVs in cancer genomes.

Rawsamble: Overlapping Nanopore Signals

A novel tool enables overlapping raw nanopore signals using a hash-based seeding mechanism, improving long-read assembly accuracy. This advancement helps resolve complex genomic regions and enables better haplotype phasing for structural variant detection.

Clinical Metagenomics Pipeline Improvements

This workflow reduces host-read contamination and speeds taxonomic profiling, helping clinical teams move faster from raw reads to actionable insights. The improved pipeline enables more rapid diagnosis of infections and better characterization of microbiome-associated conditions.

Cancer Transcript Isoform Resource

A curated isoform resource with API access enables easier exploration of cancer-specific transcript usage for biomarker discovery and validation. This resource provides comprehensive isoform annotations specifically for cancer contexts, supporting identification of biomarker candidates and therapeutic targets.